Tyers Asset Management’s Iterum Therapeutics ITRM Stock Holding History

Tyers Asset Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$154K	Sell	1,738 -72	-4%	-$7.01K	0.01%	775
2019 Q2	$187K	Sell	1,810 -337	-16%	-$37.5K	0.01%	745
2019 Q1	$259K	Sell	2,147 -514	-19%	-$47.1K	0.01%	642
2018 Q4	$200K	Hold	2,661	–	–	0.01%	678
2018 Q3	$268K	Sell	2,661 -13	-0.5%	-$1.7K	0.01%	678
2018 Q2	$437K	Buy	+2,674	New	+$483K	0.02%	474

Other funds holding ITRM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return

FCM

Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

Tyers Asset Management's ITRM Position: Q3 2019 in Review

Tyers Asset Management reduced its Iterum Therapeutics (ITRM) stake by 4% in Q3 2019, selling an estimated $7.01K and leaving 1,738 shares worth $154K. The position accounts for 0.01% of the portfolio, ranked #775.

Tyers Asset Management first reported a position in ITRM in Q2 2018 and has held it in 6 quarters since. The position peaked at $437K in Q2 2018. 19 funds tracked by Wall St. Rank hold ITRM as of Q3 2019.

Tyers Asset Management held 1,738 shares of Iterum Therapeutics worth $154K as of Q3 2019.
Tyers Asset Management sold 72 Iterum Therapeutics shares in Q3 2019, an estimated $7.01K.
Iterum Therapeutics made up 0.01% of Tyers Asset Management's portfolio in Q3 2019, its #775 holding.
Tyers Asset Management first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 6 quarters since.
Tyers Asset Management's Iterum Therapeutics position peaked at $437K in Q2 2018.
19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.